IO Biotech @IOBiotech

@IOBiotech today announced that the company intends to explore a range of strategic alternatives to maximize stockholder value. Read the full press release here: bit.ly/3YPUOCS

We are delighted to share that members of our @IOBiotech management team will be heading to San Francisco in just a few short weeks to for partnership and investor meetings on January 12-15. If you’ll be in San Francisco, we would welcome the opportunity to connect to discuss our lead investigational candidate, Cylembio, and the other candidates in our pipeline of novel off-the-shelf, immune- modulatory therapies with pan-cancer potential. Please reach out if you would like to meet with any of our team members by emailing us at info@IOBiotech.com. #JPM2026 #CancerImmunotherapy #InvestorConferences

@IOBiotech is pleased to announce the publication in Nature Communications of the long-term clinical and immunological outcomes from MM1636, the Phase 1/2 trial evaluating the investigational peptide vaccine IO102-IO103 targeting both tumor cells and immune-suppressive cells expressing IDO1 and/or PD-L1, in combination with PD-1 blockade in the treatment of first line metastatic melanoma. Read the full press release with a link to the article here: bit.ly/3MDiJCI #IOBiotech #cancerImmunotherapy #cancer

@IOBiotech is very pleased to announce that our President and CEO, Mai-Britt Zocca, PhD, will be a Speaker in the Special session with Industry, “How to translate IO research from academia to biotech”, at the ESMO Immuno-Oncology Congress 2025 taking place in London December 10 – 12, 2025. The Congress is an international event that brings together immune-oncology experts to learn, share research and expertise, and connect with other stakeholders that are making a difference in the immune-oncology field. Lecture title: IO-Biotech: Ten years journey to change the landscape of cancer vaccines Date and time: Thursday, December 11, 2025, from – GMT Learn more about the full program here: bit.ly/445Yof1 #IOBiotech #CancerImmunotherapy

@IOBiotech is pleased to announce that members of its executive management team will be attending the following upcoming December investor conferences: Event: 8th Annual Evercore Healthcare Conference Location: Coral Gables, Florida Fireside chat: Tuesday, December 2, 2025, at 7:55 am ET Participants: Mai-Britt Zocca, PhD, President & CEO, and Amy Sullivan, CFO Event: Piper Sandler 36th Annual Healthcare Conference Location: New York, New York Fireside chat: Wednesday, December 3, 2025, at 3:00 pm ET Participants: Mai-Britt Zocca, PhD, President & CEO, and Amy Sullivan, CFO See the full press release for more details and webcast links: bit.ly/4rlbcYL #IOBiotech #cancer #InvestorConferences

@IOBiotech today reported financial results for the third quarter of 2025. Read more here: bit.ly/4oJnclo #IOBiotech #cancervaccines #financialresults

@IOBiotech is pleased to announce that members of its executive management team will be attending the following upcoming investor conferences: Event: Jefferies Global Healthcare Conference Format: Company presentation Date: Tuesday, November 18, 2025, 3:00 PM GMT Presenter: Mai-Britt Zocca, PhD, President & CEO Event: Piper Sandler 36th Annual Healthcare Conference Format: Fireside chat Date: Wednesday, December 3, 2025, 3:00 PM ET Participants: Mai-Britt Zocca, PhD, President & CEO and Amy Sullivan, CFO See the full press release for more details: bit.ly/4oBy18V #IOBiotech #cancer #InvestorConferences

We are pleased to have Inés Lecoq Molinos, PhD, Senior Scientist, at the SITC Annual Meeting today to present preclinical findings on the potential of our novel investigational immune-modulatory vaccine, IO170 targeting TGF-β, to potentially enhance the treatment efficacy for a wide range of cancers. To learn more, visit the poster presentation today, November 8th from 12:15 – 1:45 PM ET in Exhibit Halls AB.

@IOBiotech today announced new pre-clinical data for its next vaccine candidate IO112 targeting arginase 1 and additional candidate IO170 targeting TGF-β, will be presented at the SITC Annual Meeting taking place in Maryland on November 5-9, 2025. Read the full press release here: bit.ly/4qLVKov

Our @IOBiotech team is proud to support Lung Cancer Awareness Month this November! Lung cancer is the leading cause of cancer deaths in the United States and globally, and it is important to encourage those at risk to take proactive steps towards prevention, detention, and early treatment. At #IOBiotech, we are dedicated to advancing research to enhance treatment options for people with multiple types of cancer, including lung cancer. For more information about our ongoing efforts and our T-win® technology platform, please visit our website: iobiotech.com

IO Biotech presented detailed results from our global Phase 3 study of investigational Cylembio® (imsapepimut and etimupepimut, adjuvanted) plus KEYTRUDA® (pembrolizumab) for the treatment of advanced melanoma at the ESMO 2025 Congress in Berlin. Read the full press release here: bit.ly/4qrb21R #IOBiotech #CancerResearch #ESMO2025

Our team is excited to be attending the ESMO 2025 Congress to connect with fellow oncology professionals from around the world. Reach out to meet with a member of our team at [email protected]. We hope to see you there! #IOBiotech #CancerResearch #ESMO25

Today we provided an update on the regulatory pathway for Cylembio® (imsapepimut and etimupepimut, adjuvanted) following a pre-BLA meeting with the U.S. Food and Drug Administration. Read the full press release here: bit.ly/3IKWqt2

@IOBiotech announced today that a late-breaking abstract has been accepted and selected as a Proffered Paper oral presentation at the 2025 European Society for Medical Oncology (ESMO) Congress taking place in Berlin, Germany from October 17-21, 2025. Read the full press release here: bit.ly/4nGsxsz

@IOBiotech is pleased to announce that Mai-Britt Zocca, PhD, President & CEO, will serve on the ‘Keeping Hope Alive: Learnings on How Pre-POC Oncology Biotechs Can Successfully Navigate Current Challenging Times’ virtual panel as part of Lumanity’s Cancer Progress Webinar taking place on September 10, 10:30 AM – 12:00 PM ET. Dr. Zocca will share her perspective on what it has taken over the past decade to successfully bring an investigational immune-modulatory therapeutic cancer vaccine from proof-of-concept through a pivotal Phase 3 clinical trial. Learn more and register for the event here: bit.ly/42kxUW5

@IOBiotech is pleased to announce that we are participating in this year’s Fierce Pharma Week taking place September 8-11 at the Pennsylvania Convention Center. Be sure to stop by and hear insights from Jolie Schafer, PhD, our National Director of Melanoma Medical Science Liaisons, who will be serving on the panel, “Bridging the Gap: Demystifying Market Access for Field Medical Teams”, on Wednesday, September 10 at 1:30 PM ET. Fierce Pharma Week is where the life sciences community truly comes together to innovate, connect, and co-create across every corner of the biopharma ecosystem. Attendees can explore over 200 cutting-edge sessions and workshops covering Pharma Marketing, PR & Communications, Medical Affairs and Commercialization! Learn more and register here: lnkd.in/gbK7J3_6

@IOBiotech is pleased to announce that members of its senior management team will be attending the following investor conferences in September: Morgan Stanley 23rd Annual Global Healthcare Conference Date: September 9, 2025, fireside chat at 7:45 AM ET Presenters: Mai-Britt Zocca, PhD, President and CEO, Amy Sullivan, CFO, and Qasim Ahmad, MD, CMO H.C. Wainwright 27th Annual Global Investment Conference Date: September 10, 2025, company presentation at 8:00 AM ET Presenters: Mai-Britt Zocca, PhD, President and CEO See the full press release for more details: bit.ly/4gb1frS #IOBiotech #cancer #InvestorConferences

@IOBiotech today reported financial results for the second quarter ended June 30, 2025. Read more: https: bit.ly/47rSvv6 #IOBiotech #cancervaccines #financialresults

Summer is the time of year when people spend more time outdoors and this Summer Sun Safety Month, @IOBiotech encourages everyone to be proactive about your skin health during the summertime and all year long. Remember to take precautions to reduce the risk of getting skin diseases and be mindful of the risks of #melanoma, a serious form of #skincancer linked to UV exposure. Learn simple changes you can make to dramatically reduce the risk of sun-related skin problems from the Skin and Cancer Institute: skinandcancerinstitute.com/its-summer-sun… To learn more about IO Biotech and our investigational T-win® immune-modulatory therapeutic cancer vaccine for the treatment of advanced melanoma, please visit our website: iobiotech.com.